New insights into the pathophysiology and clinical care of rare primary liver cancers

Gigante, Elia; Paradis, Valérie; Ronot, Maxime; Cauchy, François; Soubrane, O.; Ganne‐Carrié, Nathalie; Nault, Jean‐Charles

doi:10.1016/j.jhepr.2020.100174

Cited by 30 publications

(46 citation statements)

References 157 publications

(241 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pathologic diagnosis of cHCC‐CCA was defined as a tumour containing unequivocal elements of both hepatocytic and cholangiocytic differentiation 1,16,17 . The case of separate HCC and iCCA arising in the same liver was excluded 1,16‐18 . The biphenotypic differentiation is based on the microscopic features of haematoxylin‐eosin‐stained sections with the assistance of immunohistochemical staining results, such as hepatocyte paraffin‐1, alpha‐fetoprotein, polyclonal carcinoembryonic antigen, CK7, CK19 and/or CD10 2 .…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Clinicopathologic and MRI features of combined hepatocellular‐cholangiocarcinoma in patients with or without cirrhosis

Yoon

Hwang

Lee

et al. 2021

Liver International

View full text Add to dashboard Cite

Background and Aims Differences in combined hepatocellular‐cholangiocarcinomas (cHCC‐CCAs) arising in high‐risk patients with or without liver cirrhosis have not been elucidated. This study aimed to compare the clinicopathologic and imaging characteristics of cHCC‐CCAs in patients with or without cirrhosis and to determine the prognostic factors for recurrence‐free survival (RFS) after curative resections of single cHCC‐CCAs. Methods This retrospective study included 113 patients with surgically resected single cHCC‐CCAs who underwent preoperative magnetic resonance imaging from January 2008 to December 2019 at two tertiary referral centres. Clinical, pathologic and imaging features of tumours were compared in high‐risk patients with or without cirrhosis. Imaging features were assessed using the Liver Imaging Reporting and Data System (LI‐RADS) version 2018. RFS and associated factors were evaluated using Cox proportional hazards regression analysis, Kaplan‐Meier analysis and log‐rank test. Results cHCC‐CCAs arising from cirrhotic livers had a smaller mean tumour size (2.9 cm vs. 4.5 cm; P < .001) and were more frequently categorized as LR‐5 or 4 (41.2% vs. 20.0%; P = .024) than those arising from non‐cirrhotic livers. In multivariable analysis, a tumour size of > 3 cm (hazard ratio [HR], 2.081; 95% confidence interval [CI], 1.180‐3.668; P = .011) and the LR‐M category (HR, 2.302; 95% CI, 1.198‐4.424; P = .012) were independent predictors associated with worse RFS. Conclusions The tumour size and distribution of LI‐RADS categories of cHCC‐CCAs differed in high‐risk patients with or without cirrhosis. And LR‐M category was a worse prognosis predictor after curative resections than LR‐5 or 4 category.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Contrast‐enhanced CT or MRI examinations were performed at 3‐ to 6‐month intervals after surgery. If extrahepatic recurrence was suspected based on clinical symptoms or increasing tumour marker levels, patients underwent chest CT and 18 F‐fluorodeoxyglucose positron emission tomography scanning.…”

Section: Methodsmentioning

confidence: 99%

Clinicopathologic and MRI features of combined hepatocellular‐cholangiocarcinoma in patients with or without cirrhosis

Yoon

Hwang

Lee

et al. 2021

Liver International

View full text Add to dashboard Cite

show abstract

“…Recent evidence suggest that cHCC‐CCA have a monoclonal origin. Although some have alterations similar to ICC, molecular alterations are more frequently similar to those found in HCC 10,11 . Notably, the frequency of targetable fibroblast growth factor receptor (FGFR) fusions and isocitrate dehydrogenase (IDH)1 mutations are less frequent in combined tumours, but are still found in some patients, suggesting that a systematic approach to identifying alterations may be important for the future 12 …”

Section: Figurementioning

confidence: 99%

“…Although some have alterations similar to ICC, molecular alterations are more frequently similar to those found in HCC. 10,11 Notably, the frequency of targetable fibroblast growth factor receptor (FGFR) fusions and isocitrate dehydrogenase (IDH)1 mutations are less frequent in combined tumours, but are still found in some patients, suggesting that a systematic approach to identifying alterations may be important for the future. 12 In summary, although a consensus on the pathological definition and classification of cHCC-CCA has recently been reached, there is no similar consensus regarding optimal systemic therapy for patients with advanced disease.…”

mentioning

confidence: 99%

Combined hepatocellular‐cholangiocarcinoma – More questions than answers

Reeves

Edeline

2021

Liver International

View full text Add to dashboard Cite

“…The study clearly indicates that, although the registration of all RCTs before enrollment of participants is mandatory for publication by the International Committee of Medical Journal Editors, registration should be reinforced because it is key to transparency in trial reporting. Finally, in a review focusing on rare primary liver cancers (PLCs), Gigante et al 5 provide an update on the management of hepatocholangiocarcinoma, fibrolamellar carcinoma, hepatic hemangioendothelioma and hepatic sarcoma. The authors describe several advances in terms of pathophysiology, genetic profile and diagnosis but also discuss the limited data on PLC treatment.…”

mentioning

confidence: 99%

Celebrating the third year of JHEP Reports in the COVID-19 era

Lotersztajn¹

2021

JHEP Reports

View full text Add to dashboard Cite

When I celebrated the second year of JHEP Reports in the editorial of the first 2020 issue, 1 I could not imagine the year we would go through. But the 14 th issue of the journal is now associated with new hopes arising from vaccines that were developed at an unprecedented speed, thanks to previous solid research on related viruses and technologies, and huge financial investment. During this strange period, JHEP Reports has continued to expand, as illustrated in this issue gathering 11 basic, translational and clinical articles and 4 reviews covering liver cancer, autoimmune liver diseases, liver transplantation, non-alcoholic fatty liver disease (NAFLD) and viral hepatitis. Amaddeo et al., 2 studied the impact of the COVID-19 pandemic on the management of hepatocellular carcinoma (HCC) in Paris, in a multicentric cross-sectional study comparing the COVID-19 period to the same period in 2019. The study showed that COVID-19 clearly impacted the care of patients with liver diseases, especially those with HCC, with less patients being discussed in multidisciplinary tumor boards, especially newly diagnosed patients, and longer treatment delays. These data highlight the negative impact of the COVID-19 pandemic on HCC management. Moreover, although additional data on survival are needed to appreciate the impact of COVID-19 on liver disease progression, maintaining the usual care of patients in a pandemic is a major issue. A study by Azoulay et al. 3 aimed to reevaluate the fate of liver resection for HCC in patients with cirrhosis and significant portal hypertension, performed in highly specialized liver centers. They show that these patients can undergo liver resection with acceptable mortality, morbidity, and liver decompensation rates. The laparoscopic approach was the sole predictor of a textbook outcome. Finally, Gregory et al. 4 assessed the proportion of registered randomized controlled trials (RCTs) among RCTs on transarterial chemoembolization (TACE) for the treatment of HCC published between 2007 and 2018, using data from MEDLINE and EMBASE. The analysis shows that registration and outcome reporting in RCTs on TACE for HCC are often inadequate. The study clearly indicates that, although the registration of all RCTs before enrollment of participants is mandatory for publication by the International Committee of Medical Journal Editors, registration should be reinforced because it is key to transparency in trial reporting. Finally, in a review focusing on rare primary liver cancers (PLCs), Gigante et al. 5 provide an update on the management of hepatocholangiocarcinoma, fibrolamellar carcinoma, hepatic hemangioendothelioma and hepatic sarcoma.

show abstract

New insights into the pathophysiology and clinical care of rare primary liver cancers

Cited by 30 publications

References 157 publications

Clinicopathologic and MRI features of combined hepatocellular‐cholangiocarcinoma in patients with or without cirrhosis

Clinicopathologic and MRI features of combined hepatocellular‐cholangiocarcinoma in patients with or without cirrhosis

Combined hepatocellular‐cholangiocarcinoma – More questions than answers

Celebrating the third year of JHEP Reports in the COVID-19 era

Contact Info

Product

Resources

About